Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SERPASIL vs ALDOMET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Reserpine (Serpasil) is an indole alkaloid that depletes catecholamines (norepinephrine, dopamine) and serotonin from central and peripheral nerve endings by irreversibly binding to and inhibiting the vesicular monoamine transporter (VMAT), preventing storage of monoamines in presynaptic vesicles, leading to depletion and reduced sympathetic outflow.
Methyldopa is a centrally acting alpha-2 adrenergic agonist. Its active metabolite, alpha-methylnorepinephrine, stimulates presynaptic alpha-2 receptors in the central nervous system, reducing sympathetic outflow from the brainstem and decreasing peripheral vascular resistance, leading to lowered blood pressure.
Mild to moderate hypertension (adjunctive therapy),Psychotic disorders (off-label),Tardive dyskinesia (off-label),Huntington disease (off-label)
Hypertension (first-line in pregnancy-induced hypertension),Off-label: treatment of hypertensive crises
Hypertension: 0.1–0.25 mg orally once daily; initial dose 0.1 mg, maximum 0.5 mg/day. Psychosis (not first-line): 0.5–2 mg orally daily.
250 mg orally twice daily, increased as needed every 2-3 days; usual maintenance 500 mg to 2 g/day in 2-4 divided doses; maximum 3 g/day.
Terminal elimination half-life 45–168 hours (mean 100 h), reflecting prolonged adrenergic depletion; clinical effects persist beyond serum presence.
1.5–2 hours (terminal elimination half-life); clinical context: Renal impairment prolongs half-life (up to 4–6 hours in severe impairment), necessitating dose adjustment.
Reserpine is extensively metabolized in the liver via hydrolysis and glucuronidation; specific CYP enzymes are not well characterized.
Primarily hepatic metabolism via conjugation and O-methylation; also undergoes decarboxylation and deamination. Active metabolites include alpha-methyldopamine and alpha-methylnorepinephrine.
Primarily renal (approx. 60% unchanged and metabolites), biliary/fecal (approx. 40%), enterohepatic circulation negligible.
Renal: ~70% as unchanged drug and metabolites (sulfate conjugate, O-methylated derivatives); fecal/biliary: ~20%; <5% removed by hemodialysis.
~96% bound to plasma proteins (albumin and lipoproteins).
~10-20% bound to plasma proteins (primarily albumin).
Vd 9.4 L/kg, indicating extensive tissue binding (particularly adrenergic neurons, brain, adipose).
0.2–0.4 L/kg; clinical meaning: Moderate distribution, indicating limited extravascular penetration.
Oral: 30–40% due to extensive first-pass metabolism; IM/IV: 100%.
Oral: ~50% (range 25-60%) due to first-pass metabolism; IV: 100%.
No specific dose adjustment; use cautiously in severe renal impairment (Cr Cl <30 m L/min) due to risk of hypotension and CNS effects.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: interval every 12-24 hours; GFR <10 m L/min: interval every 24-48 hours or 250 mg every 36-48 hours.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use due to risk of hepatic encephalopathy.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or reduce dose by 75%.
Hypertension: 0.02 mg/kg/day orally divided every 6–12 hours; maximum 0.25 mg/day. Psychosis: not recommended.
10 mg/kg/day orally in 2-4 divided doses, increased gradually; maximum 65 mg/kg/day or 3 g/day.
Initiate at 0.05 mg orally once daily; increase slowly due to increased sensitivity and risk of hypotension, sedation, and depression.
Initial dose 250 mg once or twice daily; increase slowly; monitor for hypotension, sedation, and bradycardia; avoid in patients with pre-existing bradycardia or heart block.
None
None
May cause severe depression with risk of suicide (discontinue if depression occurs),Use with caution in patients with history of peptic ulcer disease (increases gastric acid secretion),Use with caution in patients with renal impairment (may reduce renal blood flow),Avoid concomitant use with MAOIs (risk of hypertensive crisis),Electroshock therapy: discontinue reserpine 7-14 days prior,May cause biliary colic in patients with gallstones,May exacerbate arrhythmias in patients with cardiac disease
Hepatic toxicity (fatal hepatic necrosis reported); hemolytic anemia (positive Coombs test common, may indicate hemolysis); sedation/drowsiness (impair mental alertness); orthostatic hypotension; caution in renal impairment (dose adjustment required); may cause positive direct Coombs test, which interferes with crossmatching; possible rebound hypertension upon abrupt discontinuation.
Hypersensitivity to reserpine or any component,History of depression (especially suicidal),Active peptic ulcer disease,Ulcerative colitis,Electroconvulsive therapy (within 7-14 days),Concurrent MAO inhibitor therapy (or within 2 weeks of discontinuation),Pheochromocytoma
Active hepatic disease (acute hepatitis, cirrhosis); prior methyldopa-induced hepatic dysfunction; concurrent MAO inhibitor therapy; hypersensitivity to methyldopa; pheochromocytoma.
Avoid tyramine-rich foods (aged cheese, cured meats, fermented products, soy sauce, yeast extracts) as reserpine can potentiate pressor responses, leading to hypertensive crisis. Alcohol may increase sedative effects. Grapefruit juice may alter drug metabolism; limit intake.
Avoid excessive sodium intake, as it can counteract the antihypertensive effect. No specific food interactions reported, but alcohol may potentiate hypotension and sedation. Iron supplements may reduce absorption of methyldopa; separate administration by at least 2 hours.
Reserpine (Serpasil) crosses the placenta. First trimester: no clear evidence of major malformations but risk of fetal bradycardia and hypothermia. Second and third trimesters: risk of neonatal bradycardia, hypotonia, lethargy, and respiratory depression. Use only if benefits outweigh risks.
First trimester: No increased risk of major congenital malformations reported in human studies based on limited data. Second and third trimesters: No known teratogenicity; use for management of chronic hypertension in pregnancy is common, but consider potential for reduced placental perfusion if maternal blood pressure is excessively lowered.
Reserpine is excreted into breast milk. M/P ratio not established. Risk of infant bradycardia, GI upset, and nasal congestion. Not recommended during breastfeeding.
Methyldopa is excreted into breast milk in small amounts (M/P ratio approximately 0.2-0.5). At typical maternal doses, infant exposure is likely subtherapeutic and considered compatible with breastfeeding. Monitor infant for potential hypotension or sedation.
No specific dose adjustment guidelines. Consider lower starting doses due to increased sensitivity. Monitor maternal blood pressure closely to avoid hypotension.
Pregnancy may increase volume of distribution and renal clearance, potentially reducing methyldopa plasma concentrations. Dose adjustments may be necessary to maintain blood pressure control; monitor and titrate based on maternal blood pressure response. Typical starting dose: 250 mg orally twice daily; maximum up to 3 g/day in divided doses, but lower doses are often effective.
Serpasil (reserpine) is an antihypertensive and antipsychotic that depletes catecholamines from peripheral sympathetic nerve endings and CNS. Onset is slow (3-6 days) and effects persist for weeks after discontinuation. Monitor for depression, especially in patients with history. Avoid in patients requiring MAOIs due to hypertensive crisis risk. Use with caution in peptic ulcer disease due to increased gastric acid secretion. Bradycardia and nasal congestion are common side effects.
ALDOMET (methyldopa) is a centrally acting alpha-2 agonist used primarily for hypertension in pregnancy. Monitor for positive direct Coombs test, which can occur in up to 20% of patients on long-term therapy; this may interfere with cross-matching but rarely causes hemolysis. Hepatic adverse effects, including increased liver enzymes and rarely hepatitis, require monitoring. Sedation and dizziness are common initially; titrate dose slowly. Methyldopa may cause orthostatic hypotension; advise patients to rise slowly. A paradoxical pressor response may occur if given with MAO inhibitors.
Take exactly as prescribed; do not stop suddenly as blood pressure may rise rapidly.,Report any symptoms of depression, mood changes, or suicidal thoughts immediately.,Avoid alcohol and over-the-counter cold or allergy medications containing decongestants.,May cause drowsiness or dizziness; avoid driving until you know how the drug affects you.,Contact your healthcare provider if you experience slow heartbeat, fainting, or severe stomach pain.
Take exactly as prescribed; do not skip doses or stop suddenly as this may cause rebound hypertension.,This medication may cause drowsiness, especially at start of therapy; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying positions to minimize dizziness or fainting.,Report any unexplained fever, fatigue, jaundice (yellowing of skin/eyes), or dark urine to your healthcare provider immediately, as these may indicate liver problems.,Notify your doctor if you experience persistent dry mouth, flu-like symptoms, or swelling in the legs.,Regular blood pressure monitoring is essential; keep a log of readings.,Avoid alcohol, as it can increase drowsiness and lower blood pressure further.,Inform all healthcare providers, including dentists, that you are taking this medication.,Do not take any other medications, including over-the-counter products, without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SERPASIL vs ALDOMET, answered by our medical review team.
SERPASIL is a Antihypertensive that works by Reserpine (Serpasil) is an indole alkaloid that depletes catecholamines (norepinephrine, dopamine) and serotonin from central and peripheral nerve endings by irreversibly binding to and inhibiting the vesicular monoamine transporter (VMAT), preventing storage of monoamines in presynaptic vesicles, leading to depletion and reduced sympathetic outflow.. ALDOMET is a Central Alpha Agonist Antihypertensive that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist. Its active metabolite, alpha-methylnorepinephrine, stimulates presynaptic alpha-2 receptors in the central nervous system, reducing sympathetic outflow from the brainstem and decreasing peripheral vascular resistance, leading to lowered blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SERPASIL and ALDOMET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SERPASIL is: Hypertension: 0.1–0.25 mg orally once daily; initial dose 0.1 mg, maximum 0.5 mg/day. Psychosis (not first-line): 0.5–2 mg orally daily.. The standard adult dose of ALDOMET is: 250 mg orally twice daily, increased as needed every 2-3 days; usual maintenance 500 mg to 2 g/day in 2-4 divided doses; maximum 3 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SERPASIL and ALDOMET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SERPASIL is classified as Category C. Reserpine (Serpasil) crosses the placenta. First trimester: no clear evidence of major malformations but risk of fetal bradycardia and hypothermia. Second and third trimesters: ris. ALDOMET is classified as Category C. First trimester: No increased risk of major congenital malformations reported in human studies based on limited data. Second and third trimesters: No known teratogenicity; use for . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.